Cargando…

The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease

Detalles Bibliográficos
Autores principales:	Drelichman, Guillermo, Castañeda‐Hernández, Gilberto, Cem Ar, Muhlis, Dragosky, Marta, Garcia, Ricardo, Lee, Howard, Moiseev, Sergey, Naderi, Majid, Rosenbaum, Hanna, Žnidar, Irena, Zuluaga, Andrés Felipe, Freisens, Selena, Mistry, Pramod K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027782/ https://www.ncbi.nlm.nih.gov/pubmed/31816110 http://dx.doi.org/10.1002/ajh.25701

Ejemplares similares

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
por: Peterschmitt, M. Judith, et al.
Publicado: (2019)

Hemorrhagic Aspects of Gaucher Disease
por: Rosenbaum, Hanna
Publicado: (2014)

The mutation spectrum in Indian patients with Gaucher disease
por: Bisariya, Vartika, et al.
Publicado: (2011)

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease
por: Adhyaru, Kunal, et al.
Publicado: (2022)

Long-read single molecule real-time (SMRT) sequencing of GBA1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe skeletal phenotypes: Collaborative study from the Argentine Group for Diagnosis and Treatment of Gaucher Disease
por: Drelichman, Guillermo I., et al.
Publicado: (2021)

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
por: Lukina, Elena, et al.
Publicado: (2018)

Rethinking fatigue in Gaucher disease
por: Zion, Y. Chen, et al.
Publicado: (2016)

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
por: Kamath, Ravi S., et al.
Publicado: (2014)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

The biosimilars journey: current status and ongoing challenges
por: Kos, Igor Age, et al.
Publicado: (2018)

Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report
por: Vujosevic, Snezana, et al.
Publicado: (2019)

The European Gaucher Alliance: a survey of member patient organisations’ activities, healthcare environments and concerns
por: Žnidar, Irena, et al.
Publicado: (2014)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries
por: Hůlková, Helena, et al.
Publicado: (2010)

The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system
por: Narayanan, Praveena, et al.
Publicado: (2022)

Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice
por: Yuen, Tony, et al.
Publicado: (2012)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Gaucher disease: an update
por: Dumitrascu, Dan L.
Publicado: (2021)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

Parkinson disease in Gaucher disease
por: Rodriguez-Porcel, Federico, et al.
Publicado: (2017)

PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
por: Symeonidis, Argiris, et al.
Publicado: (2023)

Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease
por: Goobie, Gillian C., et al.
Publicado: (2019)

Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
por: Schiffmann, Raphael, et al.
Publicado: (2022)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Population-based cohort of 500 patients with Gaucher disease in Israel
por: Jaffe, Dena H, et al.
Publicado: (2019)

Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
por: Ar, Muhlis Cem, et al.
Publicado: (2019)

Enzyme Replacement in Gaucher Disease
por: Beutler, Ernest
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_k640i9uvc6rojoa52qjpcq1lh4